AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that a poster presentation will be made at the Annual Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting to be held April 15th to April 18th, 2015 at the Gaylord Opryland Resort and Convention Center in Nashville, TN. SAGES 2015 will continue a long-standing tradition of strong didactic sessions by world-renowned experts, combined with exploration of innovative technology. The meeting will bring together Gastrointestinal and Endoscopic surgeons representing over 70 different countries.
The presentation includes results from the previously announced phase 3 results of Zalviso in abdominal patients and the phase 2 results of ARX-04 bunionectomy trial. Both studies were multi-center, randomized, double-blind and placebo-controlled.
Details on the presentation time are as follows:
|Thursday, April 16, 2015 – Emerging Technology Poster Session located in the Exhibit Hall – Presentation time 9:00am-4:00pm (local time).|
|Authors:||Neil Singla, MD; Harold Minkowitz, MD; Tong-Joo Gan, MD; Yu-kun Chiang, PhD; Karen DiDonato, MSN, RN; Pamela Palmer, MD, PhD|
|Title:||SUBLINGUAL SUFENTANIL FOR THE MANAGEMENT OF ACUTE PAIN (Original Source)|
Shares of Acelrx closed yesterday at $4.13 . ACRX has a 1-year high of $11.65 and a 1-year low of $3.58. The stock’s 50-day moving average is $5.49 and it’s 200-day moving average is $6.36.
On the ratings front, Acelrx has been the subject of a number of recent research reports. In a report issued on March 10, Jefferies Co. analyst Biren Amin downgraded ACRX to Hold, with a price target of $6, which implies an upside of 45.3% from current levels. Separately, on March 9, Mizuho’s Mario Corso downgraded the stock to Hold and has a price target of $5.59.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Biren Amin and Mario Corso have a total average return of 20.8% and 26.1% respectively. Amin has a success rate of 61.9% and is ranked #227 out of 3574 analysts, while Corso has a success rate of 68.2% and is ranked #201.
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in thedevelopment and commercialization of therapies for the treatment of acute pain.